InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

0
Player Avatar pchop123 (79.69) Submitted: 4/1/2014 3:22:20 PM : Outperform Start Price: $33.73 ITMN Score: -7.76

likely to really shoot upwards in price

Featured Broker Partners


Advertisement